

TGFβ1 (3C11): sc-130348



The Power to Question

BACKGROUND

Transforming growth factor βs (TGFβs) were originally discovered due to their ability to promote anchorage-independent growth of rat NRK fibroblasts in the presence of TGFα. It is now realized that TGFβs mediate many cell-cell interactions that occur during embryonic development. Three TGFβs have been identified in mammals. TGFβ1, TGFβ2 and TGFβ3 are each synthesized as precursor proteins that are very similar in that each is cleaved to yield a 112 amino acid polypeptide that remains associated with the latent portion of the molecules. Biologically active TGFβ requires dimerization of the monomers (usually homodimers) and release of the latent peptide portion. Overall, the mature region of the TGFβ3 protein has approximately 80% identity to the mature region of both TGFβ1 and TGFβ2. However, the NH₂ terminals or precursor regions of their molecules share only 27% sequence identity.

CHROMOSOMAL LOCATION

Genetic locus: TGFβ1 (human) mapping to 19q13.2; Tgfb1 (mouse) mapping to 7 A3.

SOURCE

TGFβ1 (3C11) is a mouse monoclonal antibody raised against recombinant TGFβ1 of human origin.

PRODUCT

Each vial contains 200 μg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

TGFβ1 (3C11) is available conjugated to agarose (sc-130348 AC), 500 μg/0.25 ml agarose in 1 ml, for IP; to HRP (sc-130348 HRP), 200 μg/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-130348 PE), fluorescein (sc-130348 FITC), Alexa Fluor® 488 (sc-130348 AF488), Alexa Fluor® 546 (sc-130348 AF546), Alexa Fluor® 594 (sc-130348 AF594) or Alexa Fluor® 647 (sc-130348 AF647), 200 μg/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor® 680 (sc-130348 AF680) or Alexa Fluor® 790 (sc-130348 AF790), 200 μg/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor® is a trademark of Molecular Probes, Inc., Oregon, USA

APPLICATIONS

TGFβ1 (3C11) is recommended for detection of TGFβ1 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

Suitable for use as control antibody for TGFβ1 siRNA (h2): sc-270322, TGFβ1 siRNA (m): sc-37192, TGFβ1 shRNA Plasmid (h2): sc-270322-SH, TGFβ1 shRNA Plasmid (m): sc-37192-SH, TGFβ1 shRNA (h2) Lentiviral Particles: sc-270322-V and TGFβ1 shRNA (m) Lentiviral Particles: sc-37192-V.

Molecular Weight of TGFβ1 monomer: 13 kDa.


Molecular Weight of TGFβ1 dimer: 25 kDa.

Positive Controls: MCF7 whole cell lysate: sc-2206, human platelet extract: sc-363773 or T-47D cell lysate: sc-2293.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA



TGFβ1 (3C11): sc-130348. Western blot analysis of human recombinant TGFβ1.

SELECT PRODUCT CITATIONS

- Xu, L., et al. 2011. Glioma-derived T cell immunoglobulin- and mucin domain-containing molecule-4 (TIM4) contributes to tumor tolerance. *J. Biol. Chem.* 286: 36694-36699.
- Qiang, G., et al. 2012. Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes. *Eur. J. Pharmacol.* 685: 156-164.
- Zhao, R., et al. 2013. Transdermal siRNA-TGFβ1-337 patch for hypertrophic scar treatment. *Matrix Biol.* 32: 265-276.
- Turato, C., et al. 2014. SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis. *Br. J. Cancer* 110: 2708-2715.
- Gonçalves, A.S., et al. 2015. Immunosuppressive mediators of oral squamous cell carcinoma in tumour samples and saliva. *Hum. Immunol.* 76: 52-58.
- Kutlu, O., et al. 2016. Antifibrogenic role of valproic acid in streptozotocin induced diabetic rat penis. *Andrologia* 48: 453-463.
- Ren, Y., et al. 2017. The Sirt1 activator, SRT1720, attenuates renal fibrosis by inhibiting CTGF and oxidative stress. *Int. J. Mol. Med.* 39: 1317-1324.
- Lv, L., et al. 2018. Rutin inhibits coronary heart disease through ERK1/2 and Akt signaling in a porcine model. *Exp. Ther. Med.* 15: 506-512.
- Daneshgaran, G., et al. 2019. A pre-clinical animal model of secondary head and neck lymphedema. *Sci. Rep.* 9: 18264.
- Sun, J., et al. 2020. Involvement of the TGFβ1 pathway in caveolin-1-associated regulation of head and neck tumor cell metastasis. *Oncol. Lett.* 19: 1298-1304.
- Kanai, R., et al. 2021. Interferon-γ enhances the therapeutic effect of mesenchymal stem cells on experimental renal fibrosis. *Sci. Rep.* 11: 850.

RESEARCH USE

For research use only, not for use in diagnostic procedures.